These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32404048)

  • 21. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of medication overuse headache across classes of treatments for acute migraine.
    Thorlund K; Sun-Edelstein C; Druyts E; Kanters S; Ebrahim S; Bhambri R; Ramos E; Mills EJ; Lanteri-Minet M; Tepper S
    J Headache Pain; 2016 Dec; 17(1):107. PubMed ID: 27882516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
    Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK
    Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701
    [No Abstract]   [Full Text] [Related]  

  • 24. Examining the utility of in-clinic "rescue" therapy for acute migraine.
    Morey V; Rothrock JF
    Headache; 2008 Jun; 48(6):939-43. PubMed ID: 18549372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The disease burden of migraine patients receiving prophylactic treatments in Korea: a population-based claims database analysis.
    Park S; Han S; Suh HS
    BMC Health Serv Res; 2022 Jul; 22(1):902. PubMed ID: 35821030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A; Leonardi M; Bussone G; D'Amico D
    Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study.
    Irimia P; García-Azorín D; Núñez M; Díaz-Cerezo S; de Polavieja PG; Panni T; Sicras-Navarro A; Sicras-Mainar A; Ciudad A
    J Headache Pain; 2022 Jul; 23(1):78. PubMed ID: 35794535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor medical care for people with migraine in Europe - evidence from the Eurolight study.
    Katsarava Z; Mania M; Lampl C; Herberhold J; Steiner TJ
    J Headache Pain; 2018 Feb; 19(1):10. PubMed ID: 29392600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness.
    Ceballos Hernansanz MA; Sanchez Roy R; Cano Orgaz A; López-Gil A;
    Clin Ther; 2003 Jul; 25(7):2053-69. PubMed ID: 12946550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription Patterns and the Cost of Migraine Treatments in German General and Neurological Practices.
    Jacob L; Kostev K
    Pain Pract; 2017 Jul; 17(6):747-752. PubMed ID: 27622427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.
    Kelley NE; Tepper DE
    Headache; 2012 Mar; 52(3):467-82. PubMed ID: 22404708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute and preventive treatment of migraine.
    Rizzoli PB
    Continuum (Minneap Minn); 2012 Aug; 18(4):764-82. PubMed ID: 22868540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain.
    Pozo-Rosich P; Carmo M; Muñiz A; Armada B; Moya-Alarcón C; Pascual J
    BMC Neurol; 2024 Apr; 24(1):107. PubMed ID: 38566063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute management of migraine.
    Chowdhury D
    J Assoc Physicians India; 2010 Apr; 58 Suppl():21-5. PubMed ID: 21049703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptan persistency among newly initiated users in a pharmacy claims database.
    Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
    Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in utilization and costs of migraine medications, 2017-2020.
    Nguyen JL; Munshi K; Peasah SK; Swart ECS; Kohli M; Henderson R; Good CB
    J Headache Pain; 2022 Aug; 23(1):111. PubMed ID: 36031609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.